First Middle Eastern-Based Gut Microbiota Study: Implications for Inflammatory Bowel Disease Microbiota-Based Therapies

Pharmacy Practice

  • Mamoon M. D. Al-Rshaidat1Laboratory for Molecular and Microbial Ecology (LaMME), Department of Biological Sciences, School of Sciences, The University of Jordan, Amman, Jordan.
  • Shaima Al-Sharif1Laboratory for Molecular and Microbial Ecology (LaMME), Department of Biological Sciences, School of Sciences, The University of Jordan, Amman, Jordan.
  • Tarek A. Tamimi2School of Medicine, The University of Jordan, Amman, Jordan.
  • Munir A. Al-Zeer3Department of Biological Sciences, School of Sciences, The University of Jordan, Amman, Jordan.
  • Jehad Samhouri2School of Medicine, The University of Jordan, Amman, Jordan.
  • Ahmad R. Alsayed4Department of Clinical Pharmacy and Therapeutics, Faculty of Pharmacy, Applied Science Private University, Amman, Jordan.
  • Yaser M. Rayyan2School of Medicine, The University of Jordan, Amman, Jordan.

Volume 23 Issue 3 Pages 1-12

DOI: 10.18549/PharmPract.2025.3.3202

Abstract

Objective: To investigate the differences in gut microbiota composition between healthy individuals and those with inflammatory bowel disease (IBD) in Jordan and to understand how these differences may contribute to the pathogenesis of IBD. Methods: This study involved the comprehensive analysis of 20 gut microbiota samples from diverse populations in Jordan. Using 16S rRNA sequencing, the gut microbiome composition of healthy individuals was compared to that of individuals with IBD. The analysis focused on microbial diversity and the relative abundance of specific bacterial taxa. Results: The study revealed significant disparities in the gut microbiota composition between healthy individuals and those with IBD. IBD patients exhibited reduced microbial diversity. There was a notable decrease in the abundance of beneficial taxa such as Firmicutes and Bacteroidetes, specifically the families Erysipelotrichaceae, Ruminococcaceae, and Lachnospiraceae. IBD patients showed elevated levels of potentially harmful bacteria, particularly the Proteobacteria phylum. Three bacterial classes, Pseudomonas, Clostridia, and Escherichia, were significantly increased in IBD patients. Beneficial genera such as Faecalibacterium prausnitzii, Bifidobacterium, Blautia, Coprococcus, and Bacteroides dorei were more prominent in healthy controls, highlighting their roles in maintaining gut health and anti-inflammatory properties. Conclusion: The findings underscore a significant association between gut microbiota dysbiosis and IBD. IBD patients in Jordan exhibited lower microbial diversity and an imbalance favoring harmful bacterial taxa. These insights into the gut microbiota composition offer a valuable understanding of IBD pathogenesis and suggest that therapeutic strategies targeting the gut microbiome could be promising for managing the disease. Further research into the interplay between gut microbiota and the immune system is essential for developing novel IBD treatments.

Keywords

  • IBD
  • Crohn's Disease
  • Ulcerative Colitis
  • gut
  • biopsy
  • microbiome
  • Roseburia
  • Faecalibacterium prausnitzii
  • Blautia
  • Coprococcus
  • Bacteroides dorei
Pharmacy Practice

Loading…